Q4 FY2025 · ended Dec 31, 2025 · Revenue $26,000, +420.0% YoY · Filed Mar 6, 2026
Altimmune, Inc. (ALT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$24.3 million. As of Jun 30, 2026 it held $518.5 million in cash and investments and $36.0 million in total debt.
Revenue
$26,000
+420.0% vs year-ago quarter
Net income
$-22.82M
-3.1% vs year-ago quarter
Operating cash flow
$-24.22M
-25.2% vs year-ago quarter
Free cash flow
$-24.25M
-25.3% vs year-ago quarter
EPS
$-0.12
+55.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
194.52M
+120.4% vs year-ago quarter
Net cash
$482.51M
Q2 FY2026
Operating margin
-111126.9%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1326190
- Former names
- PHARMATHENE, INC (until May 3, 2017); HEALTHCARE ACQUISITION CORP (until Oct 15, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $26,000 | $5,000 | $5,000 |
| Operating income | -$26.2M | -$24.2M | -$28.9M | -$20.9M | -$22.9M |
| Net income | -$22.8M | -$22.6M | -$27.4M | -$19.0M | -$22.1M |
| Diluted EPS | -$0.12 | -$0.18 | -$0.26 | -$0.21 | -$0.27 |
| Operating cash flow | -$24.2M | -$20.9M | -$19.4M | -$11.9M | -$19.4M |
| Free cash flow | -$24.3M | -$21.0M | -$19.4M | -$11.9M | -$19.4M |
| Total assets | $527.2M | $335.6M | $279.9M | $218.4M | $190.3M |
| Total liabilities | $53.0M | $51.6M | $55.0M | $32.8M | $29.0M |
| Stockholders' equity | $474.2M | $284.0M | $224.9M | $185.6M | $161.4M |
| Cash and investments | $518.5M | $331.5M | $273.5M | $210.8M | $183.1M |
| Total debt | $36.0M | $35.8M | $35.7M | $15.9M | $15.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
New debt
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 28, 2026 | Jul 28, 2026 |
All 1005 Altimmune, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.